Effect of ciprofloxacin on the pharmacokinetics of intravenous lidocaine

European Journal of Anaesthesiology

Volumn 22, Issue 10, 2005, Pages 795-799

  Isohanni, M H ^a,b   Ahonen, J ^b   Neuvonen, P J ^b   Olkkola, K T ^c  

^a Department of Anaesthesia   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Anaesthetics, local, lidocaine; Cytochrome P 450 enzyme system, cytochrome P 450 CYP1A2, antagonists and inhibitors; Pharmacokinetics, lidocaine

Indexed keywords

3 HYDROXYLIDOCAINE; CIPROFLOXACIN; DEETHYLLIDOCAINE; DRUG METABOLITE; LIDOCAINE; LIDOCARD; UNCLASSIFIED DRUG; 3-HYDROXYLIDOCAINE; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; LOCAL ANESTHETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PLASMA CLEARANCE; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANESTHETICS, LOCAL; ANTI-INFECTIVE AGENTS; BIOTRANSFORMATION; CIPROFLOXACIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LIDOCAINE; MALE;

EID: 25844523831     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0265021505001316     Document Type: Article

References (22)

1. Tucker GT, Mather LE. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet 1979; 4: 241-279.
2. Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA. Lignocaine metabolism in human liver microsomes by P450IIIA4. Clin Pharmacol Ther 1989; 46: 521-527.
3. Wang J-S, Backman JT, Wen X, Taavitsainen P, Neuvonen PJ, Kivistö KT. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol Toxicol 1999; 85: 201-205.
4. Wang J-S, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000; 28: 959-965.
5. Olkkola KT, Isohanni MH, Hamunen K, Neuvonen PJ. Effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. Anesth Analg 2005; 100: 1352-1356.
6. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 2004; 75: 80-88.
7. Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51: 1019-1074.
8. Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986; 22: 677-683.
9. Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995; 39: 305-311.
10. Nicolau DP, Nightingale CH, Tessier PR et al. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. Drugs 1995; 49(Suppl 2): 357-359.
11. Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 2003; 58: 653-657.
12. Lorec A-M, Bruguerolle B, Attolini L, Roucoules X. Rapid simultaneous determination of lidocaine, bupivacaine and their two main metabolites using capillary gas-liquid chromatography with nitrogen-phosporus detector. Ther Drug Monit 1994; 16: 592-595, 21S-28S.
13. Demedts P, Wauters A, Franck F, Neels H. Simultaneous determination of lidocaine, bupivacaine and their two main metabolites using gas chromatography and a nitrogen-phosporus detector: selection of stationary phase and chromatographic conditions. Ther Drug Monit 1996; 18: 208-211.
14. Volmer DA, Mansoori B, Locke SJ. Study of 4-quinolone antibiotics in biological samples by short-column liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Anal Chem 1997; 69: 4143-4155.
15. Keenaghan JB, Boyes RN. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther 1972; 180: 454-463.
16. Imaoka S, Enomoto K, Oda Y et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 1990; 255: 1385-1391.
17. Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol 1998; 54: 561-565.
18. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.
19. Rygnestad T, Zahlsen K, Bergslien O, Dale O. Focus on mobilisation after lower abdominal surgery. A double-blind randomised comparison of epidural bupivacaine with morphine vs. lidocaine with morphine for postoperative analgesia. Acta Anaesthesiol Scand 1999; 43: 380-387.
20. Gianelli R, Von der Groeben JO, Spicavk AP, Harrison DS. Effect of lidocaine (xylocaine) on ventricular arrhythmias in patients with coronary heart disease. New Engl J Med 1967; 277: 1215-1219.
21. Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 1978; 3: 177-201.
22. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT. The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. Anesth Analg 2000; 91: 1207-1212.